-
admin
Posts
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026,...
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had...
Gala Night of the 28th Shanghai International Film Festival Held in Shanghai
SHANGHAI, June 14, 2026 /PRNewswire/ — The Gala Night of the 28th Shanghai International Film Festival (SIFF) was held in Shanghai today, bringing together filmmakers,...
YEEDI Delivers Lowest-Ever Pricing on Self-Cleaning Roller Mop Robot Vacuums With Early Prime Day Deals
Starting June 13, M14 PLUS and S14 PLUS Drop to $399.99, Bringing Advanced Self-Cleaning Roller Mop Technology Into the Sub-$400 Segment SAN FRANCISCO, June 13,...
VEVOR Launches “Beat the Heat at Home” Summer Comfort Lineup for Outdoor Living
HOUSTON, June 13, 2026 /PRNewswire/ — As summer temperatures climb, staying cool at home shouldn’t require a sky-high electric bill, a cooler full of gas-station...
As the Lights Fade, Vivid Sydney 2026 Leaves the City Glowing
Images HERE SYDNEY, June 13, 2026 /PRNewswire/ — Off the back of 23 nights of spectacular sights, events and experiences, Vivid Sydney switches off its...
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
— Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean...
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026...
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24 months1 MonumenTAL-3 is the third...
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of...
